There's never a sure thing when it comes to decisions from the Food and Drug Administration, but when it comes to Cornerstone Therapeutics' (Nasdaq: CRTX ) drug Lixivaptan, investors have all but conceded that a complete response letter (read: rejection) is in the cards.
In the following video, health care bureau chief Brenton Flynn and analyst David Williamson discuss why the outlook is so gloomy for this drug, and how one company is looking particularly smart for cutting ties with the drug two years ago.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.